Abstract
A vaccine that targets tumor neoantigens may improve the effectiveness of nivolumab. A trial that included patients with metastatic melanoma, non–small cell lung cancer, and bladder cancer found that progression-free survival was longer than in historical controls. The vaccine also stimulated tumor-specific T cells.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
September 2019
Volume 9, Issue 9
Volume 9, Issue 9
Vaccine Increases PFS for Metastatic Tumors
Jump to section
Advertisement